HYDERABAD, India May 27, 2008 – Suven Life Sciences Ltd has announced that two product patents were granted in Russia and Australia for two of their new chemical entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases and these patents are valid until 2023.
May 27, 2008 - Optimer Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office has issued U.S. Patent No. 7,378,508 entitled "Polymorphic Crystalline Forms Of Tiacumicin B." This patent includes claims covering a novel polymorphic form of the active pharmaceutical ingredient in the investigational drug candidate, OPT-80. The patent specifically claims the Form A polymorph of OPT-80, as well as all dosage forms and pharmaceutical compositions including the Form A polymorph of OPT-80. OPT-80 is currently in two Phase 3 clinical trials for the treatment of Clostridium difficile infection, or CDI, also known as C. difficile-associated disease, or CDAD.
Lipid Sciences, Inc. announced the issuance of a second patent covering the Company's HDL Selective Delipidation technology. U.S. Patent No. 7,375,191 further extends Lipid Sciences' ownership over therapeutic HDL compositions provided by the Company's proprietary extracorporeal delipidation process.
Microbix Biosystems Inc. has been granted a patent by the State Intellectual Property Office of the People's Republic of China for its Virusmax technology which enables egg-based vaccine manufacturers to significantly increase the amount of influenza vaccine they produce each year.
May 27, 2008 - Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent Number 7,375,111 with broad claims covering sustained release (SR) compositions of bupropion and naltrexone combined in a single dosage form. These two drugs are the active constituents in Contrave, the company's lead obesity product candidate, now in Phase III clinical trials.
No comments:
Post a Comment